Moderate

Athlete's heart versus hypertrophic cardiomyopathy

Physiological vs pathological LVH · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Intense endurance or strength training produces physiological cardiac remodelling (athlete's heart) that can overlap with hypertrophic cardiomyopathy. Distinguishing benign adaptation from an inherited cardiomyopathy is vital because the latter is a leading cause of sudden death in young athletes.

Red flags

  • Exertional syncope or chest pain
  • Family history of sudden cardiac death
  • LV wall thickness >15 mm (>13 mm with other features)
  • Late gadolinium enhancement on MRI
  • Ventricular arrhythmia on monitoring

Assessment

Differential diagnosis

  • Physiological athlete's heart
  • Hypertrophic cardiomyopathy
  • Hypertensive LVH
  • Infiltrative cardiomyopathy (amyloid, Fabry)
  • Aortic stenosis LVH
  • Arrhythmogenic/other cardiomyopathy

Investigations

  • 12-lead ECG (apply athlete-specific interpretation criteria)
  • Echocardiogram (wall thickness, LV cavity size, diastolic function, strain)
  • Cardiac MRI for wall thickness, fibrosis (LGE) and morphology
  • Exercise testing for functional capacity and BP response
  • Detraining period with repeat imaging in equivocal cases
  • Genetic testing and family screening when HCM suspected

Management

  • Interpret the ECG using athlete-specific (not general-population) criteria
  • Measure LV wall thickness and cavity dimensions on echo
  • Favour athlete's heart when the LV cavity is enlarged with normal diastolic function
  • Favour HCM when there is marked asymmetric hypertrophy, small cavity, abnormal diastology or LGE
  • Assess family history of HCM or sudden cardiac death
  • Use cardiac MRI to clarify morphology and detect fibrosis
  • Consider a period of detraining with repeat imaging in the grey zone
  • Perform genetic testing if HCM features are present
  • Risk-stratify confirmed HCM for sudden cardiac death
  • Advise on sports eligibility through shared decision-making
  • Screen first-degree relatives when HCM is diagnosed
  • Arrange sports-cardiology follow-up

Drugs & doses

No drug therapy for physiological athlete's heart
Beta-blocker (e.g. bisoprolol 2.5-10 mg PO OD) if symptomatic HCM confirmed
Mavacamten 2.5-15 mg PO OD (specialist) for obstructive HCM
Avoid stimulants and performance drugs that worsen hypertrophy

Disposition

Refer to inherited cardiac conditions / sports cardiology service for grey-zone cases; family screening and eligibility counselling for confirmed HCM.

Complications & pitfalls

  • Sudden cardiac death (if HCM missed)
  • Unnecessary disqualification (if athlete's heart mislabelled)
  • Progression of undiagnosed cardiomyopathy
  • Psychological impact of diagnosis
  • Missed familial disease

Exam pearls

  • Athlete's heart typically has a dilated LV cavity, whereas HCM has a small, thick-walled cavity
  • A wall thickness of 13-15 mm is the diagnostic grey zone requiring multimodal assessment
  • Regression of hypertrophy after detraining supports physiological adaptation
  • Use athlete-specific ECG criteria to avoid over-diagnosis
  • T-wave inversion beyond V1-V2 in non-athletic distribution warrants full evaluation

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.